Potential for Developing a SARS-CoV Receptor-Binding Domain (RBD) Recombinant Protein as a Heterologous Human Vaccine Against Coronavirus Infectious Disease (COVID)-19

Human Vaccines and Immunotherapeutics - United States
doi 10.1080/21645515.2020.1740560
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

The 2019 Coronavirus (SARS-CoV-2) Surface Protein (Spike) S1 Receptor Binding Domain Undergoes Conformational Change Upon Heparin Binding.

2020English

Hypothesis: Advanced Biotechnological Treatment Approaches Against SARS-CoV-2 (COVID-19)

Volume 5 - 2020, Issue 4 - April
2020English

Optimization of Antigen Dose for a Receptor-Binding Domain-Based Subunit Vaccine Against MERS Coronavirus

Human Vaccines and Immunotherapeutics
MedicineAllergyImmunologyPharmacology
2015English

A SARS-CoV-2/COVID-19 Em Pacientes Com Câncer

Revista Brasileira de Cancerologia
2020English

Detection of Antibodies Against SARS-CoV-2 in Patients With COVID-19

Journal of Medical Virology
VirologyInfectious Diseases
2020English

Fully Human Single-Domain Antibodies Against SARS-CoV-2

2020English

Development of a SARS Coronavirus Vaccine From Recombinant Spike Protein Plus Delta Inulin Adjuvant

Methods in Molecular Biology
GeneticsMolecular Biology
2016English

Influenza Viral Infection Is a High-Risk Factor for Developing Coronavirus Disease 2019 (COVID-19)

2020English

Important Steps to Control COVID-19/SARS-CoV-2 Infection

SN Comprehensive Clinical Medicine
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy